Circulating Plasma Cell-free DNA (cfDNA) as a Predictive Biomarker for Radiotherapy: Results from a Prospective Trial in Head and Neck Cancer
Cancer Diagnosis & Prognosis · 01.09.2023 · 3 (5) · 551-557
DOI: 10.21873/cdp.10254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Diagnosis & Prognosis, online erschienen am 01.09.2023. Verfasst von Michael I Koukourakis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy - Oncology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece. Die Arbeit wurde bisher 24-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background/Aim: The plasma levels of cell-free DNA (cfDNA) in cancer patients increase due to rapid cancer cell proliferation and death. Therefore, cfDNA can be used to study specific tumor-DNA features. In addition, the non-specific cfDNA concentration may be an important biomarker of cancer prognosis. Patients and Methods: We prospectively examined the predictive role of cfDNA levels and the kinetics in the outcome of chemo-radiotherapy (CRT) in a cohort of 47 patients with locally advanced squamous cell head-neck cancer (SCHNC) treated with definitive chemo-radiotherapy.
Results
Increased cfDNA levels after therapy completion (after/before treatment ratio; A/B-ratio >1) were found in 26/47 patients (55.3%). Locally advanced T4-stage was significantly associated with higher cfDNA levels after CRT (3.3 ng/μl in T4-stage vs. 1.3 ng/μl in T1-3 stages, p=0.007). Patients who responded to CRT (partial/complete response) had significantly lower cfDNA levels before therapy (mean values 1.2 ng/μl vs. 2.7 ng/μl, p=0.03). A significantly worse locoregional progression-free survival in patients with an A/B-ratio >1 was documented (p=0.01; hazard ratio 3.5, 95%CI=1.2-9.7). This was also confirmed in multivariate analysis, where the A/B-ratio was an independent predictive variable of locoregional relapse (p=0.03, hazard ratio 3.9, 95%CI=1.2-13).
Conclusion
High post-CRT cfDNA levels could be an early biomarker for the immediate recruitment of patients with SCHNC in consolidation chemo-immunotherapy protocols.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiotherapy - Oncology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
- Radiation Oncology Unit, 1st Department of Radiology, Aretaieion University Hospital, Athens, Greece.
- Cancer Immunology and Immunotherapy Center, Cancer Research Center, Saint Savas Cancer Hospital, Athens, Greece.
- Laboratory of Biology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Zitieren
APA
Koukourakis, M. I., Xanthopoulou, E., Koukourakis, I. M., Fortis, S. P., Kesesidis, N., Karakasiliotis, I., & Baxevanis, C. N. (2023). Circulating Plasma Cell-free DNA (cfDNA) as a Predictive Biomarker for Radiotherapy: Results from a Prospective Trial in Head and Neck Cancer. Cancer Diagnosis & Prognosis, 3(5), 551-557. https://doi.org/10.21873/cdp.10254
Vancouver
Koukourakis MI, Xanthopoulou E, Koukourakis IM, Fortis SP, Kesesidis N, Karakasiliotis I, et al. Circulating Plasma Cell-free DNA (cfDNA) as a Predictive Biomarker for Radiotherapy: Results from a Prospective Trial in Head and Neck Cancer. Cancer Diagnosis & Prognosis. 2023;3(5):551-557. doi:10.21873/cdp.10254
BibTeX
@article{Koukourakis2023,
author = {Koukourakis, Michael I and Xanthopoulou, Erasmia and Koukourakis, Ioannis M and Fortis, Sotirios P and Kesesidis, Nikolaos and Karakasiliotis, Ioannis and Baxevanis, Constantin N},
title = {Circulating Plasma Cell-free DNA (cfDNA) as a Predictive Biomarker for Radiotherapy: Results from a Prospective Trial in Head and Neck Cancer},
journal = {Cancer Diagnosis & Prognosis},
year = {2023},
volume = {3},
number = {5},
pages = {551--557},
doi = {10.21873/cdp.10254}
}
EUVIMED